No abstract available
Keywords:
HSCT; acute lymphoblastic leukaemia; inotuzumab ozogamicin; relapsed; treatment cycles.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents, Immunological / administration & dosage
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Combined Modality Therapy
-
Drug Resistance, Neoplasm
-
Humans
-
Inotuzumab Ozogamicin / administration & dosage
-
Inotuzumab Ozogamicin / adverse effects
-
Inotuzumab Ozogamicin / therapeutic use*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
-
Prognosis
-
Recurrence
-
Remission Induction
-
Retreatment
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Immunological
-
Inotuzumab Ozogamicin